Findings from two studies published in the Annals of the Rheumatic Diseases suggest that people with rheumatic diseases may not have a higher risk for COVID-19 mortality and other adverse outcomes than those without.
Adding the JAK inhibitor baricitinib to remdesivir treatment reduces recovery time and improves clinical outcomes in hospitalized patients with moderate-to-severe COVID-19, suggest findings from the ACTT-2 randomized controlled trial.
People with rheumatoid arthritis have an increased risk for developing pancreatitis and pancreatic cancer compared with the general population, US study data show.
Research suggests that around three-quarters of incident gout cases could be prevented by modifying weight, diet, use of diuretics, and alcohol consumption.
Combining the QRISK3 and the EULAR modified systematic coronary risk evaluation algorithms may optimize identification of people with rheumatoid arthritis at high risk for carotid plaques, research suggests.
In patients with ACPA-negative rheumatoid arthritis, research suggests that an early response to treatment increases the likelihood of reaching sustained DMARD-free remission.
Treatment with the IL-6 receptor inhibitor tocilizumab does not improve clinical outcomes for patients with primary Sjögren’s syndrome, suggest findings from the ETAP trial.
UK research has identified a “strong dose-dependent” association between oral glucocorticoid use and CVD risk among people with immune-mediated diseases, with an increased risk seen even at doses of less than 5 mg/day.
Patients with moderate-to-severe rheumatoid arthritis treated with the JAK inhibitor baricitinib experience benefits for up to 3 years, researchers report.
Phase 2 study data suggest that subcutaneous administration is a feasible option for treatment with the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus.
Phase 3 trial results indicate that abatacept does not have significant clinical efficacy in patients with moderate-to-severe active primary Sjögren’s syndrome.
Findings from two randomized trials provide further evidence to suggest that hydroxychloroquine has no benefits for the prevention or treatment of COVID-19.
Patients with psoriatic arthritis undergoing stable treatment with tofacitinib plus methotrexate may be able to withdraw methotrexate without having an adverse impact on disease activity, suggests a substudy of the OPAL Balance trial.
Among patients with osteoarthritis, the risk for COVID-19 is not increased with the use of NSAIDs versus comparator analgesics, study findings indicate.
Use of hydroxychloroquine for the treatment of rheumatic and musculoskeletal diseases is not associated with a reduction in COVID-19 mortality risk, suggest findings from an observational study published in The Lancet Rheumatology.
An 8-week intensive course of electro-acupuncture could improve pain and function in patients with knee osteoarthritis, with the effects lasting for up to 26 weeks, Chinese research shows.